论文部分内容阅读
目的探讨雾化吸入不同剂量的布地奈德混悬液对慢性阻塞性肺疾病急性加重期(AECOPD)患者的治疗效果及安全性评估。方法84例AECOPD患者被随机分为大剂量组(30例)、一般剂量组(28例)、和对照组(26例)。三组均给予吸氧、抗菌素、氨茶碱及止咳化痰等常规治疗。大剂量组加用布地奈德混悬液4mg氧气吸入3次/天。一般剂量组加用布地奈德混悬液2mg氧气吸入3次/天。三组均治疗前及治疗后4小时、72小时、10天测定肺功能、动脉血气。治疗前后测空腹血糖、骨代谢指标。结果治疗前三组间各指标比较无明显差异(P>0.05)。治疗后4小时大剂量组与治疗前比较有显著差异性(P<0.05)而其余两组均无显著差异性(P>0.05)。治疗后72小时大剂量组和一般剂量组与治疗前比较均有显著性差异(P<0.01或P<0.05)。两组间比较也有显著性差异(P<0.05),而对照组无显著性差异。10天后三组均与治疗前比较有显著性差异(P<0.01或P<0.05)。而大剂量组与一般剂量组比较无显著性差异(P>0.05)。与对照组比较仍有显著性差异。治疗后三组间血糖、骨代谢各指标与治疗前无显著性差异(P>0.05)。结论大剂量布地奈德混悬液雾化吸入治疗AECOPD起效快而安全。
Objective To investigate the therapeutic effect and safety evaluation of inhaled budesonide suspension with different dosages on patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 84 patients with AECOPD were randomly divided into high dose group (30 cases), normal dose group (28 cases) and control group (26 cases). Three groups were given oxygen, antibiotics, aminophylline and cough and phlegm and other conventional treatment. High-dose group with budesonide suspension 4mg oxygen 3 times / day. The general dose group plus budesonide suspension inhaled 2mg oxygen 3 times / day. Three groups were treated before and after treatment 4 hours, 72 hours, 10 days determination of pulmonary function, arterial blood gas. Fasting blood glucose and bone metabolic index were measured before and after treatment. Results There was no significant difference between the three groups before treatment (P> 0.05). Four hours after treatment, there was significant difference between the high-dose group and before treatment (P <0.05) and no significant difference between the other two groups (P> 0.05). At 72 hours after treatment, there was a significant difference between the high-dose group and the normal dose group before treatment (P <0.01 or P <0.05). There was also a significant difference between the two groups (P <0.05), but there was no significant difference in the control group. After 10 days, there were significant differences between the three groups before treatment (P <0.01 or P <0.05). There was no significant difference between the high-dose group and the normal dose group (P> 0.05). Compared with the control group, there are still significant differences. After treatment, there was no significant difference between the three groups in blood glucose and bone metabolism before treatment (P> 0.05). Conclusion High-dose budesonide suspension aerosol inhalation treatment of AECOPD onset fast and safe.